At present, options include the use of interferon-alfa-based therapy and nucleos(t)ide analogues, such as lamivudine, entecavir, or adefovir. The response rate for precore mutants to interferon-alfa is low, even with a longer
duration of therapy, than that for wild-type strains or re-treatment strategies. Lamivudine, entecavir, and adefovir are regarded as safe and efficacious, but they usually require treatment over several years.